Sheriproct®

Prednisolone Caproate & Cinchocaine Hydrochloride

NEW AND
IMPROVED
LOOK

Relieve the symptoms and help support the healing process of haemorrhoids, anal fissures and pruritus ani with a combination of active ingredients that work in synergy.1,2,3

Same formulation,
same combination of benefits

Combination of synergistic ingredients; prednisolone and cinchocaine1,2,3

Relieving symptoms while supporting the healing process1,2,3

Different formats which can be used together for rapid relief1,2,3

To treat both internal and external haemorrhoids1,2,3

Effective treatment for the short-term symptomatic relief of perianal discomfort, inflammation and itching caused by thrombosed haemorrhoids, anal fissure and pruritus ani.1,2

Suppositories 12’s
Ointment 30 g
For severe symptoms, use 2-3 times a day on the first day. Thereafter, use once a day. After defecation, insert 1 suppository into the anal canal. If the suppository may have softened due to warmth, immerse in cold water before covering is removed.1

For faster relief on the first day, use up to four times a day.
Thereafter, use twice a day.
After defecation, apply ointment (pea-sized) around the anus and in
the anal ring with the finger (in very inflamed and painful conditions),
or insert into the rectum using the nozzle.2

Suppositories 12’s
For severe symptoms, use 2-3 times a day on the first day. Thereafter, use once a day. After defecation, insert 1 suppository into the anal canal. If the suppository may have softened due to warmth, immerse in cold water before covering is removed.1
Ointment 30 g

For faster relief on the first day, use up to four times a day.
Thereafter, use twice a day.
After defecation, apply ointment (pea-sized) around the anus and in
the anal ring with the finger (in very inflamed and painful conditions),
or insert into the rectum using the nozzle.2

References: 1. Scheriproct Suppositories approved package insert, 3 Aug 2000. 2. Scheriproct Ointment approved package insert, 3 Aug 2000. 3. Abramowitz L (Ed). The Diagnosis and Management of Haemorrhoidal Disease from a Global Perspective. Aliment Pharmacol Ther. 2010;31(1):1–58.

[S4] SCHERIPROCT SUPPOSITORIES. 1 suppository contains prednisolone caproate (1,4-pregnadiene-3,20-dione-11β-17α,21-triol-21-caproate) 1,3 mg and cinchocaine hydrochloride as the hydrochloride of (2-butoxy-N-(2-diethylaminoethyl)cinchonamide) 1 mg. Reg. No.: E/11.8/0668. [S4] SCHERIPROCT OINTMENT. 1 g ointment contains prednisolone caproate
(1,4-pregnadiene-3,20-dione-11β-17α,21-triol-21-caproate) 1,9 mg and cinchocaine hydrochloride as the hydrochloride of (2-butoxy-N-(2-diethylaminoethyl)cinchonamide) 5 mg. Reg. No.: E/11.8/0667. For full prescribing information refer to the professional information approved by the medicines regulatory authority.

Under licence from Karo Pharma Stockholm, Sweden. For full prescribing information refer to the professional information approved by the medicines regulatory authority.

Adcock Ingram Limited. Reg. No. 1949/034385/06. Private Bag X69, Bryanston, 2021, South Africa. Telephone + 27 11 635 0000. www.adcock.com.